Open AccessThe Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease
Author(s) -
Bo Tang,
Xue Li,
Yuanlin Liu,
Xiuhui Chen,
Ximei Li,
Yanan Chu,
Heng Zhu,
Weijiang Liu,
Fen-Fen Xu,
Fan Zhou,
Yi Zhang
Publication year - 2018
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000489689
Subject(s) - mesenchymal stem cell , homing (biology) , immune system , in vivo , icam 1 , intercellular adhesion molecule 1 , immunology , flow cytometry , biology , stem cell , mixed lymphocyte reaction , microbiology and biotechnology , cancer research , t cell , cell adhesion molecule , ecology
Mesenchymal stem cells (MSCs) do not readily migrate to appropriate sites, and this creates a major obstacle for their use in the treatment of graft-versus-host disease (GVHD). Intercellular adhesion molecule-1 (ICAM-1) can guide the homing of various immune cells to the proper anatomical location within secondary lymphoid organs (SLOs), which are the major niches for generating immune responses or tolerance. MSCs rarely migrate to SLOs after intravenous infusion, and are constitutively low expression of ICAM-1. So in our previous work, ICAM-1 was engineered into a murine MSC line C3H10T1/2 by retrovirus transfection system (ICAM-1MSCs). Here, we hypothesized that ICAM-1highMSCs may significantly improve their immunomodulatory effect.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom